ES2569513T3 - Anticuerpos antimesotelina y usos de los mismos - Google Patents
Anticuerpos antimesotelina y usos de los mismos Download PDFInfo
- Publication number
- ES2569513T3 ES2569513T3 ES08855189.0T ES08855189T ES2569513T3 ES 2569513 T3 ES2569513 T3 ES 2569513T3 ES 08855189 T ES08855189 T ES 08855189T ES 2569513 T3 ES2569513 T3 ES 2569513T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- antibody
- mesothelin
- protein
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000003735 Mesothelin Human genes 0.000 abstract description 55
- 108090000015 Mesothelin Proteins 0.000 abstract description 55
- 239000000427 antigen Substances 0.000 abstract description 11
- 102000036639 antigens Human genes 0.000 abstract description 11
- 108091007433 antigens Proteins 0.000 abstract description 11
- 239000012634 fragment Substances 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 description 61
- 102000004169 proteins and genes Human genes 0.000 description 59
- 108020004414 DNA Proteins 0.000 description 51
- 210000004027 cell Anatomy 0.000 description 48
- 238000001514 detection method Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 11
- 241001529936 Murinae Species 0.000 description 10
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 10
- 239000013598 vector Substances 0.000 description 9
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 8
- 102100023123 Mucin-16 Human genes 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 6
- 239000010931 gold Substances 0.000 description 6
- 229910052737 gold Inorganic materials 0.000 description 6
- 230000009260 cross reactivity Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 230000009824 affinity maturation Effects 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 229960005091 chloramphenicol Drugs 0.000 description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- GYNXTHOOAGYMOK-UHFFFAOYSA-N 2-hydroxybutanediamide Chemical compound NC(=O)CC(O)C(N)=O GYNXTHOOAGYMOK-UHFFFAOYSA-N 0.000 description 2
- 241001429175 Colitis phage Species 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- -1 crushing Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 241000735235 Ligustrum vulgare Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101001046961 Mus musculus Keratin, type II cytoskeletal 1 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US437807P | 2007-11-26 | 2007-11-26 | |
| US4378P | 2007-11-26 | ||
| PCT/EP2008/009756 WO2009068204A1 (en) | 2007-11-26 | 2008-11-19 | Anti-mesothelin antibodies and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2569513T3 true ES2569513T3 (es) | 2016-05-11 |
Family
ID=40351874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08855189.0T Active ES2569513T3 (es) | 2007-11-26 | 2008-11-19 | Anticuerpos antimesotelina y usos de los mismos |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US9023351B2 (enExample) |
| EP (3) | EP2215121B1 (enExample) |
| JP (3) | JP5608091B2 (enExample) |
| KR (1) | KR101559599B1 (enExample) |
| CN (2) | CN101952319B (enExample) |
| AU (1) | AU2008329221B2 (enExample) |
| BR (1) | BRPI0819909B8 (enExample) |
| CA (1) | CA2706529C (enExample) |
| CO (1) | CO6280409A2 (enExample) |
| CR (1) | CR11456A (enExample) |
| CU (1) | CU23833A3 (enExample) |
| CY (1) | CY1117437T1 (enExample) |
| DK (1) | DK2215121T3 (enExample) |
| DO (1) | DOP2010000150A (enExample) |
| EC (1) | ECSP10010191A (enExample) |
| ES (1) | ES2569513T3 (enExample) |
| GT (1) | GT201000148A (enExample) |
| HN (1) | HN2010001062A (enExample) |
| HR (1) | HRP20160485T1 (enExample) |
| HU (1) | HUE027358T2 (enExample) |
| IL (1) | IL205681A0 (enExample) |
| MA (1) | MA31862B1 (enExample) |
| MX (1) | MX2010005603A (enExample) |
| MY (1) | MY157164A (enExample) |
| NZ (1) | NZ585551A (enExample) |
| PL (1) | PL2215121T3 (enExample) |
| SI (1) | SI2215121T1 (enExample) |
| TN (1) | TN2010000234A1 (enExample) |
| UA (1) | UA106036C2 (enExample) |
| WO (1) | WO2009068204A1 (enExample) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ584633A (en) * | 2007-10-01 | 2011-11-25 | Bristol Myers Squibb Co | Human antibodies that bind mesothelin, and uses thereof |
| AU2008329221B2 (en) * | 2007-11-26 | 2013-11-07 | Bayer Intellectual Property Gmbh | Anti-mesothelin antibodies and uses therefor |
| AR076284A1 (es) * | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| PH12013501323A1 (en) * | 2010-12-20 | 2013-08-28 | Genentech Inc | Anti-mesothelin antibodies and immunoconjugates |
| EP3138581B1 (en) | 2011-03-17 | 2019-01-02 | The University of Birmingham | Re-directed immunotherapy |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| RU2610336C2 (ru) | 2011-04-21 | 2017-02-09 | Сиэтл Дженетикс, Инк. | Новые конъюгаты связывающее соединение - активное соединение (adc) и их применение |
| US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
| US9416190B2 (en) * | 2012-09-27 | 2016-08-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin antibodies and methods for eliciting potent antitumor activity |
| CN103819559B (zh) * | 2013-12-10 | 2016-02-24 | 中国科学院武汉病毒研究所 | 一种抗间皮素纳米抗体及其编码基因和该纳米抗体的用途 |
| PE20160996A1 (es) | 2013-12-23 | 2016-11-09 | Bayer Pharma AG | Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp |
| US10392447B2 (en) | 2014-09-30 | 2019-08-27 | Neurimmune Holding Ag | Human-derived anti-dipeptide repeats (DPRs) antibody |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| DK3298033T4 (da) | 2015-05-18 | 2023-10-02 | Tcr2 Therapeutics Inc | Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner |
| CN108025084B (zh) | 2015-06-22 | 2024-08-09 | 拜耳医药股份有限公司 | 具有酶可裂解基团的抗体药物缀合物（adc）和抗体前药缀合物（apdc） |
| EP3316908A4 (en) * | 2015-06-30 | 2019-03-06 | Henlius Biotech Co., Ltd. | VASCULAR ENDOTHELIAL GROWTH FACTOR ANTI-RECEPTOR 2 (VEGFR2) ANTIBODY |
| BR112018003339A8 (pt) | 2015-08-21 | 2022-10-18 | Carsgen Therapeutics Ltd | Anticorpos antimesotelina completamente humanos e células imunoefetoras que direcionam mesotelina |
| KR101782487B1 (ko) | 2015-09-24 | 2017-09-27 | 재단법인 목암생명과학연구소 | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| EP4643874A2 (en) | 2015-12-22 | 2025-11-05 | Novartis AG | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
| EP4219689A3 (en) | 2015-12-30 | 2023-12-20 | Novartis AG | Immune effector cell therapies with enhanced efficacy |
| EP3418304B1 (en) * | 2016-02-15 | 2021-08-04 | Kanagawa Prefectural Hospital Organization | Recognition of membrane type mucin-like protein and clinical application thereof |
| KR20180118175A (ko) | 2016-03-04 | 2018-10-30 | 노파르티스 아게 | 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도 |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| CA3018630A1 (en) | 2016-03-24 | 2017-09-28 | Bayer Pharma Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| KR20180134385A (ko) | 2016-04-15 | 2018-12-18 | 노파르티스 아게 | 선택적 단백질 발현을 위한 조성물 및 방법 |
| TW201806972A (zh) | 2016-05-27 | 2018-03-01 | 美商艾伯維生物醫療股份有限公司 | 雙特異性結合蛋白 |
| EP3919518A1 (en) | 2016-06-15 | 2021-12-08 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| JP7085708B2 (ja) | 2016-06-20 | 2022-06-17 | エフ－スター セラピューティクス リミテッド | Ｌａｇ－３結合要素 |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| EP3490590A2 (en) | 2016-08-01 | 2019-06-05 | Novartis AG | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| US20190218294A1 (en) | 2016-09-09 | 2019-07-18 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
| BR112019007100A2 (pt) | 2016-10-07 | 2019-06-25 | Tcr2 Therapeutics Inc | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| MY191926A (en) | 2016-12-01 | 2022-07-18 | Regeneron Pharma | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| RU2761390C2 (ru) | 2016-12-21 | 2021-12-07 | Байер Фарма Акциенгезельшафт | Конъюгаты связующего и активного вещества (adc), имеющие ферментативно расщепляемые группы |
| JP7174704B2 (ja) | 2016-12-21 | 2022-11-17 | バイエル・アクチエンゲゼルシヤフト | 酵素開裂基を有する細胞毒性活性剤のプロドラッグ |
| CN110072556B (zh) | 2016-12-21 | 2023-05-02 | 拜耳制药股份公司 | 具有ksp抑制剂的特异性抗体药物缀合物(adc) |
| EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| WO2018232020A1 (en) | 2017-06-13 | 2018-12-20 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| JP6339283B1 (ja) | 2017-10-31 | 2018-06-06 | 国立大学法人 岡山大学 | Ｄｎａ、ポリペプチド、抗メソセリン抗体、腫瘍イメージング剤及び複合体 |
| WO2019105835A1 (en) | 2017-11-29 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib and anetumab ravtansine |
| EP3728316B1 (en) | 2017-12-19 | 2025-02-26 | invoX Pharma Limited | Fc binding fragments comprising a pd-l1 antigen-binding site |
| EP3730612A4 (en) * | 2017-12-24 | 2021-09-01 | Noile-Immune Biotech, Inc. | IMMUNOCOMPETENT CELL THAT EXPRESSES A CELL SURFACE MOLECULE THAT SPECIFICALLY RECOGNIZES HUMAN MESOTHELIN, IL-7 AND CCL19 |
| MA52712A (fr) | 2018-04-27 | 2021-03-31 | Biogen Ma Inc | Anticorps anti-(poly-ga) dirigé contre des répétitions dipeptidiques (dpr) d'origine humaine |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| US20210123075A1 (en) | 2018-06-08 | 2021-04-29 | Novartis Ag | Compositions and methods for immunooncology |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| US12344672B2 (en) | 2018-07-12 | 2025-07-01 | Invox Pharma Limited | Antibody molecules that bind PD-L1 and CD137 |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| EP3820898B1 (en) | 2018-07-12 | 2025-09-03 | invoX Pharma Limited | Antibody molecules that bind cd137 and ox40 |
| CN109053882B (zh) * | 2018-08-28 | 2019-08-23 | 东莞市朋志生物科技有限公司 | 一种ns1蛋白的结合蛋白以及应用 |
| WO2020047501A1 (en) | 2018-08-30 | 2020-03-05 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CN119896730A (zh) | 2018-12-17 | 2025-04-29 | 雷维托普有限公司 | 双免疫细胞衔接物 |
| JP2022514315A (ja) | 2018-12-20 | 2022-02-10 | ノバルティス アーゲー | ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ |
| EP3924054B1 (en) | 2019-02-15 | 2025-04-02 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| AU2020222346B2 (en) | 2019-02-15 | 2021-12-09 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| MX2021011040A (es) * | 2019-03-14 | 2021-12-10 | Morphosys Ag | Anticuerpos dirigidos contra c5ar. |
| JP7684947B2 (ja) | 2019-03-19 | 2025-05-28 | フンダシオ プリバダ インスティトゥト ディンベスティガシオ オンコロジカ デ バル エブロン | 癌の治療のための併用療法 |
| WO2020234114A1 (en) | 2019-05-21 | 2020-11-26 | Bayer Aktiengesellschaft | A novel stable high concentration formulation for anetumab ravtansine |
| US20220267437A1 (en) * | 2019-07-29 | 2022-08-25 | Fred Hutchinson Cancer Research Center | Methods and compositions for inducing notch signaling in tumor microenvironments |
| CN119684459A (zh) | 2019-12-20 | 2025-03-25 | 安进公司 | 治疗实体瘤的靶向间皮素的cd40激动性多特异性抗体构建体 |
| US20230057071A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
| WO2021252920A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| JP2023531676A (ja) | 2020-06-23 | 2023-07-25 | ノバルティス アーゲー | ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン |
| CN116134027B (zh) | 2020-08-03 | 2025-01-24 | 诺华股份有限公司 | 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| CN116063527A (zh) * | 2021-09-30 | 2023-05-05 | 南京北恒生物科技有限公司 | 靶向间皮素的抗体及其用途 |
| TW202321296A (zh) | 2021-10-06 | 2023-06-01 | 美商鏈接免疫療法公司 | 抗間皮素抗原結合分子及其用途 |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| EP4581052A1 (en) | 2022-09-01 | 2025-07-09 | University of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
| CN120166937A (zh) | 2022-10-25 | 2025-06-17 | 佩普托米克公司 | 用于治疗癌症的联合疗法 |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| CN116019939A (zh) * | 2022-11-24 | 2023-04-28 | 华中科技大学同济医学院附属协和医院 | 靶向msln的分子探针以及用途 |
| EP4626930A2 (en) * | 2022-12-02 | 2025-10-08 | Jecho Laboratories, Inc. | Anti-mesothelin bispecific antibodies and methods of use |
| WO2024226827A2 (en) | 2023-04-25 | 2024-10-31 | Arsenal Biosciences, Inc. | Novel receptors for transcription regulation |
| AU2024276994A1 (en) | 2023-05-24 | 2025-10-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2024251854A1 (en) | 2023-06-07 | 2024-12-12 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy with braf inhibitors for the treatment of cancer |
| EP4473974A1 (en) | 2023-06-07 | 2024-12-11 | Peptomyc, S.L. | Omomyc and kras inhibitors combination therapy for the treatment of cancer |
| CN121335714A (zh) | 2023-06-07 | 2026-01-13 | 瓦尔希伯伦私人肿瘤研究基金会 | 用于治疗癌症的与mek抑制剂的组合疗法 |
| CN117659133B (zh) * | 2023-12-06 | 2024-09-20 | 南京鼓楼医院 | 间皮素靶向结合蛋白、其编码核酸以及用途 |
| CN117843793B (zh) * | 2024-03-07 | 2024-07-09 | 深圳真实生物医药科技有限公司 | 抗间皮素抗体、抗原结合片段及其用途 |
| WO2025235862A1 (en) | 2024-05-10 | 2025-11-13 | Inndura Therapeutics Inc. | A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US6180377B1 (en) * | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| DE69621940T2 (de) | 1995-08-18 | 2003-01-16 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
| ES2212071T3 (es) | 1996-01-05 | 2004-07-16 | The Government Of The United States Of America, As Represented By The Secretary, Department Of | Antigeno de mesotelio y kits para marcarlo como diana. |
| DE69833459T2 (de) | 1997-12-01 | 2006-08-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendung |
| US6809184B1 (en) * | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
| ATE328280T1 (de) * | 1999-02-26 | 2006-06-15 | Pacific Northwest Res Inst | Verfahren und zusammensetzungen zur karzinomdiagnose |
| ES2327382T3 (es) | 1999-07-20 | 2009-10-29 | Morphosys Ag | Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro. |
| WO2006099141A2 (en) | 2005-03-10 | 2006-09-21 | Morphotek, Inc. | Anti-mesothelin antibodies |
| US20090047211A1 (en) * | 2005-05-12 | 2009-02-19 | The Govt. Of The U.S. As Represented By The Sec. Of The Dept. Of Health And Human Services | Anti-mesothelin antibodies useful for immunological assays |
| RS53743B1 (sr) | 2005-05-18 | 2015-06-30 | Morphosys Ag | Anti-gm-csf antitela i njihova upotreba |
| EP1891113A2 (en) | 2005-06-02 | 2008-02-27 | AstraZeneca AB | Antibodies directed to cd20 and uses thereof |
| NZ584633A (en) * | 2007-10-01 | 2011-11-25 | Bristol Myers Squibb Co | Human antibodies that bind mesothelin, and uses thereof |
| AU2008329221B2 (en) * | 2007-11-26 | 2013-11-07 | Bayer Intellectual Property Gmbh | Anti-mesothelin antibodies and uses therefor |
-
2008
- 2008-11-19 AU AU2008329221A patent/AU2008329221B2/en not_active Ceased
- 2008-11-19 HU HUE08855189A patent/HUE027358T2/en unknown
- 2008-11-19 EP EP08855189.0A patent/EP2215121B1/en active Active
- 2008-11-19 PL PL08855189T patent/PL2215121T3/pl unknown
- 2008-11-19 CA CA2706529A patent/CA2706529C/en active Active
- 2008-11-19 DK DK08855189.0T patent/DK2215121T3/en active
- 2008-11-19 CN CN200880125390.8A patent/CN101952319B/zh not_active Expired - Fee Related
- 2008-11-19 CN CN201410396441.8A patent/CN104151429B/zh not_active Expired - Fee Related
- 2008-11-19 NZ NZ585551A patent/NZ585551A/en not_active IP Right Cessation
- 2008-11-19 MX MX2010005603A patent/MX2010005603A/es active IP Right Grant
- 2008-11-19 EP EP16170412.7A patent/EP3103814A1/en not_active Withdrawn
- 2008-11-19 EP EP13168583.6A patent/EP2634196A1/en not_active Ceased
- 2008-11-19 KR KR1020107011375A patent/KR101559599B1/ko not_active Expired - Fee Related
- 2008-11-19 UA UAA201008006A patent/UA106036C2/uk unknown
- 2008-11-19 ES ES08855189.0T patent/ES2569513T3/es active Active
- 2008-11-19 HR HRP20160485TT patent/HRP20160485T1/hr unknown
- 2008-11-19 JP JP2010535269A patent/JP5608091B2/ja not_active Expired - Fee Related
- 2008-11-19 WO PCT/EP2008/009756 patent/WO2009068204A1/en not_active Ceased
- 2008-11-19 SI SI200831603A patent/SI2215121T1/sl unknown
- 2008-11-19 MY MYPI2010002379A patent/MY157164A/en unknown
- 2008-11-19 BR BRPI0819909A patent/BRPI0819909B8/pt not_active IP Right Cessation
- 2008-11-19 US US12/744,849 patent/US9023351B2/en active Active
-
2010
- 2010-05-11 IL IL205681A patent/IL205681A0/en active IP Right Grant
- 2010-05-20 GT GT201000148A patent/GT201000148A/es unknown
- 2010-05-20 DO DO2010000150A patent/DOP2010000150A/es unknown
- 2010-05-21 CO CO10061059A patent/CO6280409A2/es not_active Application Discontinuation
- 2010-05-21 CU CU2010000098A patent/CU23833A3/es active IP Right Grant
- 2010-05-21 HN HN2010001062A patent/HN2010001062A/es unknown
- 2010-05-21 EC EC2010010191A patent/ECSP10010191A/es unknown
- 2010-05-21 CR CR11456A patent/CR11456A/es unknown
- 2010-05-24 MA MA32865A patent/MA31862B1/fr unknown
- 2010-05-25 TN TN2010000234A patent/TN2010000234A1/fr unknown
-
2014
- 2014-07-03 JP JP2014137893A patent/JP2014221064A/ja active Pending
-
2015
- 2015-03-11 US US14/645,411 patent/US20150259433A1/en not_active Abandoned
-
2016
- 2016-04-27 CY CY20161100353T patent/CY1117437T1/el unknown
-
2018
- 2018-03-05 US US15/911,748 patent/US20180258181A1/en not_active Abandoned
- 2018-03-05 JP JP2018038254A patent/JP6717869B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2569513T3 (es) | Anticuerpos antimesotelina y usos de los mismos | |
| CN107406495B (zh) | 治疗及检测癌症的组合物及方法 | |
| CN113474362B (zh) | 对cd44特异性的抗体 | |
| CN117447599A (zh) | 对muc18特异性的抗体 | |
| CN112955548B (zh) | 叶酸受体α特异性抗体 | |
| ES2753419T3 (es) | Inhibidores del factor H del complemento | |
| ES2818948T3 (es) | Composiciones para la supresión del cáncer por inhibición de TMCC3 | |
| CN117343187A (zh) | 对muc18特异性的抗体 | |
| JP6486914B2 (ja) | ヒト抗ｉｌ−３２抗体 | |
| US20230220053A1 (en) | ANTI-SARS-CoV-2 ANTIBODIES AND USES THEREOF | |
| CN114641307A (zh) | 抗cd19抗体及其用途 | |
| WO2013185193A1 (pt) | Método de produção e obtenção de variáveis de fragmento fab do anticorpo monoclonal anti-digoxina a partir da técnica de clonagem em biologia molecular. | |
| CN117264056A (zh) | Nrp-1抗体及其用途 | |
| HK40060752B (en) | Antibodies specific to muc18 | |
| HK40060753A (en) | Antibodies specific to muc18 | |
| HK1200856B (en) | Anti-mesothelin antibodies and uses therefor | |
| HK1148541B (en) | Anti-mesothelin antibodies and uses therefor |